Everything below concerns Prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
=== Q: Congenital malformations, deformations and chromosomal abnormalities === (Q18.0) Sinus, fistula and cyst of branchial cleft Congenital preauricular fistula: A small pit in front of the ear. Also known as an ear pit or preauricular sinus. (Q26.6) Portal vein-hepatic artery fistula (Q38.0) Congenital fistula of lip (Q38.4) Congenital fistula of salivary gland (Q42.0) Congenital absence, atresia and stenosis of rectum with fistula (Q42.2) Congenital absence, atresia and stenosis of anus with fistula (Q43.6) Congenital fistula of rectum and anus (Q51.7) Congenital fistulae between uterus and digestive and urinary tracts (Q52.2) Congenital rectovaginal fistula
=== Other enterprises === C.P. Company, an Italian apparel brand Cedar Point, an amusement park in Sandusky, Ohio, US Central Partnership, a Russian film distributor and production company Charoen Pokphand (C.P. Group), a Thai agribusiness conglomerate Chicago Pneumatic, an American manufacturer of tools and equipment Colgate-Palmolive, an American consumer goods company Commercial Press, a Chinese publishing company Connaught Place, New Delhi, a commercial centre in India Curious Pastimes, a UK-based gaming company
== History and development == A recipe for cream soda written by E. M. Sheldon and published in Michigan Farmer in 1852 called for water, cream of tartar (potassium bitartrate), Epsom salts, sugar, egg, and milk to be mixed, then heated, then mixed again once cooled with water and a quarter teaspoonful of baking soda to make an effervescent drink. It was suggested as a temperance drink preferable to those of "Uncle Bacchus" and in compliance with the recently introduced Maine law. An alternative recipe can be found combining a soda of choice as well as whipped cream. Alexander C. Howell of Vienna, New Jersey, was granted a patent for "cream soda-water" on June 27, 1865. Howell's cream soda-water was made with sodium bicarbonate, water, sugar, egg whites, wheat flour, and "any of the usual flavoring materials—such as oil of lemon, extracts of vanilla, pine-apple, to suit the taste". Before drinking, the cream soda-water was mixed with water and an acid, such as tartaric acid or citric acid. In Canada, James William Black of Berwick, Nova Scotia, was granted a U.S. patent on December 8, 1885, and a Canadian patent on July 5, 1886, for "ice-cream soda". Black's ice-cream soda, which contained whipped egg whites, sugar, lime juice, lemons, citric acid, flavoring, and bicarbonate of soda, was a concentrated syrup that could be reconstituted into an effervescent beverage by adding ordinary ice water. In the United States, Ugo H. Sodini helped to pioneer in the creation of vanilla cream soda.
Sources: en.wikipedia.org
Manipulation of CpG-S and CpG-N sequences in the plasmid backbone of DNA vaccines can ensure the success of the immune response to the encoded antigen and drive the immune response toward a TH1 phenotype. This is useful if a pathogen requires a TH response for protection. CpG-S sequences have also been used as external adjuvants for both DNA and recombinant protein vaccination with variable success rates. Other organisms with hypomethylated CpG motifs have demonstrated the stimulation of polyclonal B-cell expansion. The mechanism behind this may be more complicated than simple methylation – hypomethylated murine DNA has not been found to mount an immune response. Most of the evidence for immunostimulatory CpG sequences comes from murine studies. Extrapolation of this data to other species requires caution – individual species may require different flanking sequences, as binding specificities of scavenger receptors vary across species. Additionally, species such as ruminants may be insensitive to immunostimulatory sequences due to their large gastrointestinal load.
These grafts were synthesized as a graft copolymer of microfibrillar type I collagen and a glycosaminoglycan, chondroitin-6-sulfate, fabricated into porous sheets by freeze-drying, and then cross-linked by dehydrothermal treatment. Control of the structural features of the collagen scaffold (average pore size, degradation rate and surface chemistry) was eventually found to be a critical prerequisite for its unusual biological activity. In 1981 Burke and Yannas proved that their artificial skin worked on patients with 50 to 90 percent burns, vastly improving the chances of recovery and improved quality of life. John F. Burke also claimed, in 1981, "[The Artificial skin] is soft and pliable, not stiff and hard, unlike other substances used to cover burned-off skin." Several patents were granted to MIT for the creation of collagen-based grafts that can induce dermis regeneration. U.S. Patent 4,418,691 (December 6, 1983) was cited by the National Inventors Hall of Fame as the key patent describing the invention of a process for regenerated skin (Inductees Natl. Inventors Hall of Fame, 2015). These patents were later translated into a commercial product by Integra LifeSciences Corp., a company founded in 1989. Integra Dermal Regeneration Template received FDA approval in 1996, and the FDA listed it as a "Significant Medical Device Breakthrough" in the same year.
=== Recreational use === A herbal remedy called Krypton was found to contain kratom leaf powder and desmetramadol. Krypton was reportedly linked to at least 9 accidental opioid overdose deaths in Sweden during 2010–2011.
Sources: en.wikipedia.org
== History and literature == The compound was discovered by Justus von Liebig and Friedrich Wöhler. It is one of the oldest named organic compounds. It was originally prepared in 1818 by Luigi Valentino Brugnatelli (1761-1818) and was named in 1838 by Wöhler and Liebig. The name "Alloxan" emerged from an amalgamation of the words "Allantoïn" and "Oxalsäure" (oxalic acid). The alloxan model of diabetes was first described in rabbits by Dunn, Sheehan, and McLetchie in 1943. The name is derived from allantoin, a product of uric acid excreted by the fetus into the allantois, and oxaluric acid derived from oxalic acid and urea, found in urine. Alloxan was used in the production of the purple dye murexide, discovered by Carl Wilhelm Scheele in 1776. Murexide is the product of the complex in-situ multistep reaction of alloxantin and gaseous ammonia. Murexide results from the condensation of the unisolated intermediate uramil with alloxan liberated during the course of the reaction.
However, the details of how serpin polymers cause cell death remains to be fully understood. Physiological serpin polymers are thought to form via domain swapping events, where a segment of one serpin protein inserts into another. Domain-swaps occur when mutations or environmental factors interfere with the final stages of serpin folding to the native state, causing high-energy intermediates to misfold. Both dimer and trimer domain-swap structures have been solved. In the dimer (of antithrombin), the RCL and part of the A-sheet incorporates into the A-sheet of another serpin molecule. The domain-swapped trimer (of antitrypsin) forms via the exchange of an entirely different region of the structure, the B-sheet (with each molecule's RCL inserted into its own A-sheet). It has also been proposed that serpins may form domain-swaps by inserting the RCL of one protein into the A-sheet of another (A-sheet polymerisation). These domain-swapped dimer and trimer structures are thought to be the building blocks of the disease-causing polymer aggregates, but the exact mechanism is still unclear.
A neuron is called identified if it has properties that distinguish it from every other neuron in the same animal—properties such as location, neurotransmitter, gene expression pattern, and connectivity—and if every individual organism belonging to the same species has exactly one neuron with the same set of properties. In vertebrate nervous systems, very few neurons are "identified" in this sense. Researchers believe humans have none—but in simpler nervous systems, some or all neurons may be thus unique. In vertebrates, the best known identified neurons are the gigantic Mauthner cells of fish. Every fish has two Mauthner cells, located in the bottom part of the brainstem, one on the left side and one on the right. Each Mauthner cell has an axon that crosses over, innervating (stimulating) neurons at the same brain level and then travelling down through the spinal cord, making numerous connections as it goes. The synapses generated by a Mauthner cell are so powerful that a single action potential gives rise to a major behavioral response: within milliseconds the fish curves its body into a C-shape, then straightens, thereby propelling itself rapidly forward. Functionally of this is a fast escape response, triggered most easily by a strong sound wave or pressure wave impinging on the lateral line organ of the fish. Mauthner cells are not the only identified neurons in fish—there are about 20 more types, including pairs of "Mauthner cell analogs" in each spinal segmental nucleus.
=== Ka–Ke === Henrik Kacser FRSE (1918–1995). British geneticist and biochemist at Edinburgh, founder of metabolic control analysis. Emil T. Kaiser (1938–1988). Hungarian-born American protein chemist at the University of Chicago, known for his work on enzyme modification. Member Natl. Acad. Sci. USA. Herman Kalckar (1908–1991). Danish biochemist at the New York Public Health Research Institute, who worked on cellular respiration, nucleotide metabolism and galactose metabolism. Member Natl. Acad. Sci. USA Nathan O. Kaplan (1917–1986) Enzymologist at UC San Diego, founding editor of Methods in Enzymology. Member Natl. Acad. Sci. USA Sir Bernard Katz FRS (1911–2003). German-British neuroscientist and biophysicist at University College London. Nobel Prize in Physiology or Medicine (1970) for work on nerve biochemistry and the pineal gland. Stuart Alan Kauffman (b. 1939). American theoretical biologist, expert on complex systems, now at the University of Pennsylvania. Fellow of the Royal Society of Canada. Douglas Kell (b. 1953). British biochemist at the University of Manchester, known for research on functional genomics, metabolomics and the yeast genome. John Kendrew FRS (1917–1997). British x-ray crystallographer at the European Molecular Biology Laboratory, Heidelberg, known for determining the crystal structure of myoglobin. Nobel Prize in Chemistry (1962). Sir Ernest Kennaway FRS (1881–1958), British pathologist at the Institute of Cancer Research, London, who carried out early work on carcinogenic effects of hydrocarbons. Eugene P.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.